Jiangxi Synergy Pharmaceutical (300636.SZ): The raw material drug of Telmisartan Potassium has been approved by the China Food and Drug Administration (CDE).
Tonghe Pharmaceutical Co., Ltd. (300636.SZ) announced that the company recently received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CD...
Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently obtained the approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The company's submission for the raw material of "Valsartan Potassium" has been approved by the CDE. Valsartan Potassium is used for the treatment of primary hypertension in adults.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
